Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?'

Clin Exp Dermatol. 2022 Oct;47(10):1864-1865. doi: 10.1111/ced.15291. Epub 2022 Jul 12.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adalimumab / therapeutic use
  • Biological Therapy
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Infliximab / therapeutic use
  • Referral and Consultation

Substances

  • Infliximab
  • Adalimumab